Vanqua Bio

We welcome Hunter Smith to Vanqua Bio’s Board of Directors. With over 30 years of leadership experience in global finance and management roles across multiple industries, Hunter brings a wealth of expertise and strategic vision to our team. As CFO of Rhythm Pharmaceuticals since 2017, Hunter led the company's IPO and subsequently raised additional capital totaling over $1 billion. Previously, Hunter made significant contributions at Celgene and Bunge Limited, and served on the boards of Aeglea BioTherapeutics and Genessee & Wyoming Inc. Hunter will work with the Board of Directors and the executive team to help strengthen our organization as we progress our evolution as a clinical-stage company. #NewBoardMember #Leadership

Our team took part at The Michael J. Fox Foundation for Parkinson's Research, Chicago Run/Walk this past Sunday. It was inspiring to see so many come together in support of a future without #Parkinsons.

Calling all runners and walkers! Join us in supporting The Michael J. Fox Foundation for Parkinson's Research, Chicago Run/Walk. Register today and be part of the movement: https://lnkd.in/eCFatTGt 100% of the funds raised go directly to Parkinson's research programs. #ParkinsonsDisease #OutrunPD

Calling all runners and walkers! Join us in supporting The Michael J. Fox Foundation for Parkinson's Research, Chicago Run/Walk. Register today and be part of the movement: https://lnkd.in/eCFatTGt 100% of the funds raised go directly to Parkinson's research programs. #ParkinsonsDisease #OutrunPD

We are pleased to share American Chemical Society’s vol. 35 of Building Chemistry’s Future newsletter. It features an interview with our own Chief Scientific Officer Kevin Hunt. Kevin is an alum of ACS’s Project SEED, the program enabling talented, economically disadvantaged high school students to have a hands-on chemistry research experience in professional labs. SEED also helps students learn about and prepare for college and careers in science. Read the interview to learn about the catalytic power of Project SEED that led Kevin into biotech to work on developing medicines with a potential to improve people’s lives. He also supports the program that helps young people from underprivileged backgrounds to realize their love of chemistry into meaningful careers. To support the mission of Project SEED, visit www.donate.acs.org

The 30th annual Parkinson's Unity Walk, organized by The Michael J. Fox Foundation for Parkinson's Research, is taking place on April 27th in Central Park, NYC. Join the fight against Parkinson's disease by registering today. All ages and abilities are welcome! https://bit.ly/3xIZ4d1 #UnityWalk #EndParkinsons

April is Parkinson’s Disease Awareness Month. Today, on #WorldParkinsonsDay, we celebrate the significant progress that the PD community has made in our understanding of the disease and recognize the urgent need for effective disease-modifying therapies. At Vanqua Bio, our mission is to help usher in a new era of hope for the millions of people living with neurodegenerative diseases, such as Parkinson's. #ParkinsonsAwareness

We are pleased to share that the first patient has been dosed in a first-in-human, Phase 1 clinical study evaluating VQ-101, a novel GCase activator for the treatment of GBA-Parkinson’s Disease. This milestone underscores our commitment to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases. Learn more about the study: https://bit.ly/3Wac85t #NeurodegenerativeDiseases #Parkinsons #ClinicalResearch

Our CEO Jim Sullivan will present at the Stifel 2024 CNS Days Conference on Tuesday, March 19, 4-4:25 p.m. ET. To learn more, visit: https://bit.ly/3v9X5gR #neurosciences #cns

We are looking forward to #ADPD2024! We will be presenting posters discussing the pre-clinical characterization of VQ-101 and the development of a novel assay enabling the assessment of GCase activity in live cells across multiple species, including humans. To learn more, visit: https://bit.ly/48PgHEY